Juvenescence

Juvenescence

Private
DublinHealthcare & Life Scienceshttps://www.juvlabs.com

Last Round

Series B

Extension

May 21, 2025

Est. Valuation

$500M

Total Funding Raised

$162.3M

Company Overview

Juvenescence is a biotechnology company that develops medicines and therapies designed to extend healthy human lifespan by targeting the core mechanisms of aging.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical AI, D2C Brands

Business Model

B2B

Customer Profile

Subscription SaaS, Hardware Sales

AI Layer

Non-AI

Keywords

longevity therapeuticslongevity biotechhealthspan extensionanti-aging biotechdrug development pipelineage-related diseasesgeroscienceclinical-stage biotechAI drug discoverybiotech venture modelPAI-1 inhibitorketone supplementconsumer health products

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Juvenescence Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Juvenescence Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionMay 21, 2025
Series BAug 19, 2019
Series AJun 11, 2018
SeedJan 8, 2018

Key People

Founding team and executive leadership

Richard Marshall

Chief Executive Officer

Executive Team

David Gill

CFO

Executive Team

Gerson Montenegro

Chief Operating Officer - COO

Executive Team

Juvenescence Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 30, 2025

    Attended the Middle East Investors Summit in Abu Dhabi.

  • Jun 5, 2025

    Acquired Ro5 Inc. for $76 million.

Juvenescence Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Juvenescence Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Juvenescence's valuation, stock price, and market status.

Firmographic Details

HeadquartersDublin
Employee Range42
Year Founded2016
Last FundingMay 21, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.